HRTX Q2 2025 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$162M

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$37M+3.3% YoY

Gross Profit

$27M73.5% margin

Operating Income

-$2M-4.4% margin

Net Income

-$2M-6.4% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-4.4%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$232M

Total Liabilities

$259M

Stockholders' Equity

-$27M

Cash & Equivalents

$17M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$37M	$36M	+3.3%
Gross Profit	$27M	$26M	+7.2%
Operating Income	-$2M	-$6M	+74.6%
Net Income	-$2M	-$9M	+74.2%

Revenue Segments

C I N V A N T I

$24M70%

Z Y N R E L E F

$8M24%

S U S T O L

$2M7%